List of Biotech, Pharmaceutical & Life Sciences companies in Delaware - 37

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

Adesis Inc. is a premier chemistry solution company backed by expert chemists and partnering with biotech and pharma industries to accelerate their research and manufacturing goals. Through the years, we've retained our original culture anchored in ethics, integrity, values, family, transparency, speed, safety and trust. We are one of the few companies that can turn a difficult whiteboard chemistry concept into a physical product. We specialize in organic and organometallic synthesis and deliver organic chemistry services in three areas: early-stage research, scale-up and development, and specialty manufacturing. Our turnaround times are recognized as among the fastest in the industry – a direct result of minimizing red tape, maximizing lab time and quick, efficient decision-making. When clients say ‘let's begin,' we've already started. The companion to this remarkable speed is our commitment to safety. The Adesis Facility Safety Program is designed to constantly raise the level of awareness of safe work practices. Our vigilance extends to the protection of client patents and intellectual property. Backed by the effective use of systems, security and formalized processes, client confidentiality is always a priority. We pride ourselves on our chemists being respected for their brilliance and enthusiasm to collaborate and adapt. If a client needs to shift, we pivot quickly to provide the necessary facilities and specialist brainpower to address any challenge and keep the project moving. The compounds we develop for clients have found use in life-enhancing oncology, anti-infective, animal treatment, central nervous system, immunotherapy, therapeutic, ophthalmic, biomarkers, skin care, catalysts and other applications. Reliably and safely solving the toughest chemistry problems in partnership with its clients is the core purpose of Adesis. Trusted collaboration with exceptional chemistry teams. In Adesis hands, the science is not complicated.

Amalgam Rx empowers patients and providers to make the best decisions possible—within clinical workflows and in everyday life. With a modular SaMD platform, EHR solutions, and Medical-Grade Al, Amalgam partners with global life sciences companies, health plans, and providers to reimagine care delivery. Today, Amalgam’s Al-powered solutions support nearly 10 million patients across four continents and have enabled more than 70 million clinical decisions.

Founded in 2002, ANP Technologies, Inc. is an emerging nanobiotechnology company with a major focus on design, development, and marketing of innovative technologies. ANP Technologies, Inc. is a nanobiotechnology company with cutting-edge technology platforms focused on: • Specialty CRO for biological drug R&D • Biodefense and homeland security • Home/point-of-care diagnostic systems • Nanoencapsulation and targeted drug delivery and therapy

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company’s product candidates, AL101 and AL102, were licensed into Ayala from Bristol Myers Squibb. Our lead product candidate AL101 is currently in Phase 2 clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, for patients bearing Notch-activating mutations. Our second product candidate AL102 is being developed for the treatment of desmoid tumors. In addition, we are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies. The company is based in the US and Israel.

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company. BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.

Providing value-based care to our community, ONE PERSON AT A TIME. ChristianaCare, headquartered in Wilmington, Delaware, is one of the country's largest health care providers, ranking 22nd in the nation for hospital admissions. ChristianaCare is a major teaching hospital with two campuses and more than 250 Medical-Dental residents and fellows. ChristianaCare is recognized as a regional center for excellence in cardiology, cancer and women's health services. The system is home to Delaware's only Level I trauma center for adults and children, the only center of its kind between Philadelphia and Baltimore. ChristianaCare also features a Level III neonatal intensive care unit, the only delivering hospital in the state to offer this level of care for newborns. A not-for-profit, non-sectarian health system, ChristianaCare includes two hospitals with more than 1,100 patient beds, a home health care service, preventive medicine, rehabilitation services, a network of primary care physicians and an extensive range of outpatient services. With more than 11,600 employees, ChristianaCare is the largest private employer in Delaware and among the top 10 in the Philadelphia region. Statistics at a Glance: Among hospitals in the United States, ChristianaCare's ranking by volume is: 22nd in admissions. 32nd in births. 24th in emergency visits. 32nd in total surgeries. Among hospitals on the East Coast, ChristianaCare ranks: 12th in admissions. 16th in births. 15th in emergency visits. 19th in total surgeries. (Source: American Hospital Association Annual Survey Database of 6,200 U.S. Hospitals, 2017, © Health Forum, LLC) Awards: Christiana Care is continually recognized for excellence on a regional and national level. These are some of our recent awards. Click to see more at http://www.christianacare.org/Awards

We are an energetic team with a mission to provide an affordable solution that is both configurable and secure. CloudLIMS is built exclusively on cloud-based technology to give you a product that requires no investment in IT resources or manpower. The seamless and integrated workflows allow you to concentrate on research and innovation so that managing an informatics solution is the least of your worries. Email at support@cloudlims.com or call at +1 (302) 789-0447 to request a personalized demo!

CorriXR Therapeutics is an oncology-focused biotherapeutics development company with a ground-breaking gene editing platform technology. The company is headquartered in Wilmington, Delaware, United States.

Delaware State University hasempoweredstudents to turn their dreams into reality for over 125 years as one of the nation’s premier Historically Black Colleges and Universities(HBCU).

Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The unique and proprietary technology owned by Dermaliq, called hyliQ, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of superior, highly effective liquid drug products with exceptional cosmetic properties.

Enovis is a data analytics company that provides technology solutions for business intelligence and information management.

EOLO PHARMA is a pharmaceutical company that focuses on drug discovery and developing novel molecules for the treatment of obesity.

Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Stock Exchange. The company engages in the pharmaceutical sector and focuses on developing innovative drugs for various medical conditions such as prostate cancer, asthma, and COPD. Foresee Pharmaceuticals has a diverse set of clinical and development candidates with distinct profiles and patents.

Gene Editing Institute V1 is a biotechnology company that advances the power of CRISPR gene editing technology to improve human life through groundbreaking research and development.

Geneyx offers best-in-class practices harnessing #geneticdata available to guide digital insights for rare and #germline disorders and diseases. We aim to enrich disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and #pharmaceutical organizations.

GenKardia's mission is to deliver innovative therapies to improve the lives of patients battling Heart Failure

Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list. For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.

Inteliquet, an IQVIA business, Inteliquet is a leading provider of innovative technology and comprehensive support services for cancer clinical researchers. We bridge sponsors, patients and cancer centers nationwide for the ultimate purpose of increasing patient access to cancer trial treatment options. From trial selection to patient matching, Inteliquet enables a streamlined and more accurate journey to patient enrollment. To learn more about Inteliquet, visit https://inteliquet.com/

LEVY Health's clinical decision support software empowers OB-GYNs to swiftly identify endocrine disorders and aids fertility clinics in streamlining complex work-ups. This reduces the time to diagnoses from years to mere weeks, ensuring a more efficient and effective path to parenthood

NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes and animals. Our technology targets two special cellular components known as organelles that harbor their own DNA. Those organelles are called mitochondria and chloroplasts. Both organelles are important to create energy for cells to grow. They are also critical for producing various biochemical molecules key to specific pathways and functions. Our genome technology has broad application areas. They range from industrial biotechnology to animal and human healthcare as well as to agriculture. Our mission is to harness the potentials of organelles to make our society a better place to live.

Neurolixis Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system diseases including movement disorders, autism spectrum disorders, depression and pain.

We create innovative, life-saving treatments and bring hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. We apply our unique clinical and scientific expertise, partnered with leading medical experts, to develop known molecules for medical conditions with no indicated therapies. NRx believes in a world where scientific advancement makes untreatable diseases treatable. We are committed to bringing new treatments and hope for people with chronic medical conditions so they may live full lives.

Patient Sortal is a blockchain-based healthcare data management system for patients with ongoing medical conditions such as chronic diseases or disabilities.

Precisio Biotix Therapeutics is US incorporated industry leader in precision antibacterial biological solutions; specifically the identification and development of lysin and phage products to combat bacterial infections or difficult to treat bacterial issues. Products created with lysins and phages are novel precision solutions to address the declining effectiveness of existing treatments. LysiThru™,the Company's industry-leading, high-throughput lysin screening system, is capable of rapidly creating new gram-positive and gram-negative lysins for almost every pathogen. The Company has a robust pipeline of commercial products with both Rx and consumer commercial opportunities. - Multiple gram positive and gram negative systemic lysins, with a focus on skin and lung infections. - Bactelide™, a sustained release biodegradable phage product to prevent and treat topical infections - Several topical lysins with consumer-oriented uses

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.

Progentos Therapeutics is a biotech company focused on developing treatments for multiple sclerosis and other neuropsychiatric disorders. The company has raised $65 million in Series A financing and will have operations in Watertown, MA, USA and Naarden, The Netherlands.

RevOpsis Therapeutics is a next-generation biopharmaceutical company that is trailblazing a new era in multispecific antibody discovery and development to unlock transformative treatments for complex disease. Our process is simple. Our proprietary Rev-Mod Platform uses a modular plug-and-play system to streamline drug discovery and development. The Rev-Mod Platform features a library of ~30 billion fully human and fully compatible antibody components that are ready to be assembled into functional Multi-Mod biologics. Using this platform, we can select and integrate multiple antibody components into a single, multispecific therapeutic molecule that binds targets implicated in known, clinically validated disease pathways. Our lead asset from this platform, RO-104, is a first-in-class trispecific biologic. RO-104 targets 3 clinically validated pathways that are implicated in retinal vascular diseases, such as neovascular age-related macular degeneration (nAMD). Whereas current anti-VEGF therapies used to treat nAMD predominantly target only the VEGF-A pathway, RO-104 builds on a body of literature that suggests that combining the targeting of VEGF-A, VEGF-C, and Ang-2 can improve patients’ therapeutic gains and extend treatment durability. RO-104 has the potential to offer these benefits with a single therapeutic molecule, as preclinical studies indicate high affinity to all 3 targets, efficacy in a choroidal neovascularization model, and ideal drug-like properties.

At Sensible Biotechnologies, we are turning living cells into cost-efficient factories for manufacturing high-quality mRNA to unlock the full potential of mRNA therapeutics and vaccines. 

Silony Spine is disrupting the spinal surgery marketplace with compatible options for enabling technology systems. Check out our portfolio of precision tools and hardware that add significant value and freedom of choice.

StimuSIL is a medical device company developing proprietary technologies for safer and more effective light therapy. We intend for our products to be used across multiple indications in dermatology and aesthetics. We’ve established a team of leading experts in the dermatology, aesthetics, pharmaceuticals, biomedical engineering, and regulatory science fields to lead the research and development across our medical device pipeline. For more information, visit https://www.stimusil.com/

Superbrewed Foodis a biotechnology company founded upon synthetic biology and bio-process development. They are developing solutions for global challenges by harnessing the natural advantages of microorganisms called Clostridia.

Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets. We are dedicated to the discovery and development of best-in-class therapeutics that can improve the lives of people living with cancer. Leveraging deep expertise in cancer biology and a world class medicinal chemistry team, we are building a diverse pipeline of novel small molecule targeted therapies. Our mission is to efficiently advance these agents into clinical trials with the goal of transforming cancer care through patient-focused precision medicine.

Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world. Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.

At Virion Therapeutics, We Believe a Future Free of Cancer and Chronic Infectious Diseases Is Within Reach​ Driven by science, our mission is to revolutionize the immunotherapy treatment landscape, focusing on the development of novel, adaptable, and accessible CD8+ T cell-based technologies.​ Our transformative platform is first in its class, offering a unique methodology that combines innovative and established approaches to elicit a superior CD8+ T cell response. Novel genetically encoded checkpoint modifiers are delivered alongside optimized target-specific antigens via an immunogenic and adaptable viral vector platform that promotes potent, prolonged, and broad CD8+ T cell responses. With potential applications across a range of cancers and chronic infectious diseases, our proprietary technology provides us with a robust pipeline. Our lead product, VRON-0200, is under investigation as a potential functional cure for the treatment of chronic hepatitis B virus (HBV) – a first-in-human clinical study is planned to initiate in late 2022. Founded in 2018 to advance technology licensed from The Wistar Institute, we have assembled a world-class management team and an industry-leading global Board of Directors, with proven experience in the biotechnology sector, as well as extensive preclinical and clinical expertise in antiviral, vaccine, oncology, and immuno-oncology.​

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 12,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $4.5 billion.